Abstract
The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with a history of at least four basal cell carcinomas (BCCs) and/or cutaneous squamous cell carcinomas (SCCs) were entered into a randomized, double-blind, placebo-controlled trial, performed in free-standing study clinics. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5-10 mg), or placebo supplementation daily for 3 years. The time to first new occurrence of BCC or cutaneous SCC was used as the outcome measure. During the study period, 319 BCCs and 125 cutaneous SCCs were diagnosed clinically and pathologically. There were no differences between those who received retinol, isotretinoin, or the placebo, with regard to the time to first occurrence or to the total number of tumors noted. No beneficial effects were noted with regard to the prevention of nonmelanoma skin cancer with either retinol or isotretinoin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 957-961 |
| Number of pages | 5 |
| Journal | Cancer Epidemiology Biomarkers and Prevention |
| Volume | 6 |
| Issue number | 11 |
| State | Published - 1997 |
Fingerprint
ASJC Scopus subject areas
- Epidemiology
- Oncology
Cite this
Trial of retinol and isotretinoin in skin cancer prevention : A randomized, double-blind, controlled trial. / Levine, Norman; Moon, Thomas E.; Cartmel, Brenda; Bangert, Jerry L.; Rodney, Steven; Dong, Qiong; Peng, Yei Mei; Alberts, David S.
In: Cancer Epidemiology Biomarkers and Prevention, Vol. 6, No. 11, 1997, p. 957-961.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Trial of retinol and isotretinoin in skin cancer prevention
T2 - A randomized, double-blind, controlled trial
AU - Levine, Norman
AU - Moon, Thomas E.
AU - Cartmel, Brenda
AU - Bangert, Jerry L.
AU - Rodney, Steven
AU - Dong, Qiong
AU - Peng, Yei Mei
AU - Alberts, David S
PY - 1997
Y1 - 1997
N2 - The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with a history of at least four basal cell carcinomas (BCCs) and/or cutaneous squamous cell carcinomas (SCCs) were entered into a randomized, double-blind, placebo-controlled trial, performed in free-standing study clinics. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5-10 mg), or placebo supplementation daily for 3 years. The time to first new occurrence of BCC or cutaneous SCC was used as the outcome measure. During the study period, 319 BCCs and 125 cutaneous SCCs were diagnosed clinically and pathologically. There were no differences between those who received retinol, isotretinoin, or the placebo, with regard to the time to first occurrence or to the total number of tumors noted. No beneficial effects were noted with regard to the prevention of nonmelanoma skin cancer with either retinol or isotretinoin.
AB - The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with a history of at least four basal cell carcinomas (BCCs) and/or cutaneous squamous cell carcinomas (SCCs) were entered into a randomized, double-blind, placebo-controlled trial, performed in free-standing study clinics. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5-10 mg), or placebo supplementation daily for 3 years. The time to first new occurrence of BCC or cutaneous SCC was used as the outcome measure. During the study period, 319 BCCs and 125 cutaneous SCCs were diagnosed clinically and pathologically. There were no differences between those who received retinol, isotretinoin, or the placebo, with regard to the time to first occurrence or to the total number of tumors noted. No beneficial effects were noted with regard to the prevention of nonmelanoma skin cancer with either retinol or isotretinoin.
UR - http://www.scopus.com/inward/record.url?scp=0030840112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030840112&partnerID=8YFLogxK
M3 - Article
C2 - 9367070
AN - SCOPUS:0030840112
VL - 6
SP - 957
EP - 961
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 11
ER -